200 related articles for article (PubMed ID: 28374831)
1. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
Qasaimeh MA; Wu YC; Bose S; Menachery A; Talluri S; Gonzalez G; Fulciniti M; Karp JM; Prabhala RH; Karnik R
Sci Rep; 2017 Apr; 7():45681. PubMed ID: 28374831
[TBL] [Abstract][Full Text] [Related]
2. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
3. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
4. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
Chai KY; Boyke Berahmana AA; Morison IM
Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
[No Abstract] [Full Text] [Related]
5. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
6. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
[TBL] [Abstract][Full Text] [Related]
7. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
8. Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.
Kamande JW; Lindell MAM; Witek MA; Voorhees PM; Soper SA
Integr Biol (Camb); 2018 Feb; 10(2):82-91. PubMed ID: 29372735
[TBL] [Abstract][Full Text] [Related]
9. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
11. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
12. Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma.
Krishnan SR; Luk F; Brown RD; Suen H; Kwan Y; Bebawy M
Neoplasia; 2016 Jan; 18(1):25-32. PubMed ID: 26806349
[TBL] [Abstract][Full Text] [Related]
13. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
[TBL] [Abstract][Full Text] [Related]
16. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
[No Abstract] [Full Text] [Related]
17. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
18. CD138 shedding in plasma cell myeloma.
Grigoriadis G; Whitehead S
Br J Haematol; 2010 Aug; 150(3):249. PubMed ID: 20433680
[No Abstract] [Full Text] [Related]
19. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
20. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
